3 Drug Stocks to Buy at a Discount

Eli Lilly's leadership in GLP-1 weight-loss drugs has driven its P/E to about 53 and compressed its dividend yield to ~0.6%, well above the pharmaceutical sector average P/E of ~30 and average yield ~1.3%. By contrast, Merck (P/E ~14, yield 3.2%, payout ratio ~45%), Bristol Myers Squibb (P/E ~18, yield 4.7%, payout ratio ~85%) and Pfizer (P/E ~15, yield 6.8%, payout ratio >100%) trade at much lower valuations and offer materially higher yields. The article frames these gaps as driven by investor enthusiasm for GLP-1s and notes patent-cliff timing and R&D cadence as the primary fundamentals risk, implying a contrarian case for value-oriented investors to consider the larger, dividend-rich incumbents.

Analysis

Market structure: GLP-1 leaders (LLY, market leaders in article) are clear winners today — investors are paying a P/E ~53 versus sector ~30, compressing yields (LLY yield ~0.6%) and concentrating valuation risk. Incumbent large-cap pharmas (MRK P/E 14, BMY 18, PFE 15) are the short-term losers in sentiment but retain diversified pipelines and cashflows; their higher yields (MRK 3.2%, BMY 4.7%, PFE 6.8%) reflect this re‑pricing and create an income/duration play versus growth names.

Competitive dynamics & supply/demand: rapid demand growth for GLP-1s increases pricing power for leaders but invites capacity expansion, biosimilars, and payor pushback over 6–36 months — suggesting margins may compress as the class commoditizes. Patent cliffs and asynchronous R&D timing (next 12–36 months) mean MRK/BMY/PFE face temporary revenue gaps but also create M&A optionality and buyback/dividend-supported floors to equity value.

Risk assessment: tail risks include regulatory safety/reimbursement interventions for GLP-1s (low-probability, high-impact within 3–12 months), major trial failures at incumbents, or unexpected patent litigation outcomes. Short-term (days–weeks) expect headline-driven volatility; medium (3–12 months) depends on trial readouts/FDA decisions; long-term (1–3 years) depends on pipeline replenishment and generic dynamics.

Contrarian implication: sentiment appears overdone—payor/regulatory constraints and capacity expansion should reduce leader multiple if sales normalize; conversely, undervalued incumbents can re-rate if they deliver 2–3 new approvals or M&A within 12–24 months. Look for specific catalysts (FDA decisions, quarterly guidance, patent expiry notices) in next 30–180 days to tilt allocation.

Key Decisions for Investors

• Establish a 2–3% portfolio long in MRK and a separate 2–3% long in BMY within the next 2–6 weeks, scaling into a 5–10% drawdown; horizon 12–36 months to capture dividend income (target total yield+capital gain >6% p.a. if re-rate) and pipeline maturation.
• Create a 3–4% income collar on PFE (buy shares, sell 3-month calls 5–10% OTM, buy 6–9 month puts ~5% OTM) within 10 trading days to harvest the 6.8% yield while limiting downside from payout sustainability risk; roll collars quarterly.
• Implement a relative-value pair trade: long MRK (1.5–2% notional) vs. short LLY (1–1.5% notional) to express reversion of the P/E gap; cap risk by sizing short <= long and target unwind if LLY down >20% or MRK P/E >20 (timeframe 6–12 months).
• Buy LEAP call exposure to BMY (12–18 month calls 25–35% OTM or a debit call spread to limit premium) sized 0.5–1% notional to play potential re-rating from pipeline/approval catalysts; re-assess after next two quarterly earnings/FDA milestones (30–180 days).